Tenet Healthcare (THC) EVP earns 37,785 performance-based stock shares

Rhea-AI Filing Summary

Tenet Healthcare Corp executive Thomas W. Arnst reported an equity award of 37,785 shares of common stock. The Form 4 shows these shares were acquired at a price of $0.00 per share as a grant or award, bringing his directly held common stock to 37,785 shares.

According to the footnote, this represents performance-based restricted stock that was earned when the Human Resources Committee certified achievement of performance targets tied to goals measured over the period from January 1, 2023 to December 31, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arnst Thomas W

(Last) (First) (Middle)

14201 DALLAS PARKWAY

(Street)

DALLAS TX 75254

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Admin. Officer & GC

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A(1)		37,785	A	$0	37,785	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of performance-based restricted stock that was earned on the date the Human Resources Committee of the Company certified the achievement of the applicable performance targets based on the extent to which the applicable performance goals were attained for the performance period of January 1, 2023 to December 31, 2025.

	Chad J. Wiener, as Attorney-in-fact for Thomas W. Arnst	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tenet Healthcare (THC) report for Thomas W. Arnst?

Tenet Healthcare reported that executive Thomas W. Arnst acquired 37,785 shares of common stock through a grant. The shares were awarded at no cash cost, reflecting performance-based restricted stock earned under previously established incentive criteria.

How many Tenet Healthcare (THC) shares does Thomas W. Arnst hold after this Form 4?

After the reported transaction, Thomas W. Arnst directly holds 37,785 shares of Tenet Healthcare common stock. The entire reported position reflects the performance-based restricted stock award earned and credited to his ownership on the transaction date.

What type of equity award did Tenet Healthcare (THC) grant to Thomas W. Arnst?

The award is performance-based restricted stock that was earned after the Human Resources Committee certified performance target achievement. It ties to goals measured for the period from January 1, 2023 through December 31, 2025 under the company’s incentive framework.

Did Thomas W. Arnst pay cash for the Tenet Healthcare (THC) shares reported?

No cash was paid for these shares; the Form 4 lists a price of $0.00 per share. The 37,785 Tenet Healthcare shares were received as a grant of performance-based restricted stock rather than an open-market purchase.

What role does Thomas W. Arnst hold at Tenet Healthcare (THC)?

Thomas W. Arnst serves as Executive Vice President, Chief Administrative Officer, and General Counsel at Tenet Healthcare. His reported equity grant reflects compensation linked to company performance over a defined multi-year performance period.